Evaxion Biotecch (EVAX)
(Delayed Data from NSDQ)
$2.75 USD
+0.05 (1.72%)
Updated Aug 14, 2024 03:21 PM ET
After-Market: $3.09 +0.34 (12.30%) 5:02 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Evaxion Biotech AS Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 22 | 25 | 26 | 17 | 11 |
Income After Depreciation & Amortization | -22 | -25 | -26 | -17 | -11 |
Non-Operating Income | 1 | 3 | 2 | 0 | 0 |
Interest Expense | 2 | 2 | 1 | 0 | 1 |
Pretax Income | -23 | -24 | -25 | -17 | -12 |
Income Taxes | -1 | -1 | 0 | -2 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -22 | -23 | -25 | -15 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -22 | -23 | -25 | -15 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -22 | -25 | -25 | -16 | -11 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -22 | -25 | -26 | -17 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.34 | 2.36 | 1.95 | 1.54 | NA |
Diluted EPS Before Non-Recurring Items | -0.81 | -9.80 | -12.60 | -9.70 | NA |
Diluted Net EPS (GAAP) | -8.10 | -9.80 | -12.60 | -9.70 | NA |
Fiscal Year end for Evaxion Biotech AS Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.05 | 0.07 | 0.00 | 0.00 |
Cost Of Goods | NA | NA | 0.00 | NA | 0.00 |
Gross Profit | NA | 0.05 | 0.07 | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.45 | 4.44 | 5.76 | 5.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.40 | -4.37 | -5.76 | -5.68 |
Non-Operating Income | NA | 5.62 | 0.56 | 0.07 | 0.05 |
Interest Expense | NA | 0.25 | 0.90 | 0.18 | 0.28 |
Pretax Income | NA | 0.98 | -4.70 | -5.87 | -5.91 |
Income Taxes | NA | -0.22 | -0.18 | -0.19 | -0.23 |
Minority Interest | NA | NA | 0.00 | NA | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | NA | 0.00 |
Other Income/Charges | NA | NA | 0.00 | NA | 0.00 |
Income From Cont. Operations | NA | 1.19 | -4.52 | -5.68 | -5.68 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 1.19 | -4.52 | -5.68 | -5.68 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 46.64 | 29.06 | 2.77 | 2.64 |
Diluted EPS Before Non-Recurring Items | NA | 0.03 | -0.16 | -2.10 | -2.10 |
Diluted Net EPS (GAAP) | NA | 0.03 | -0.16 | -2.10 | -2.10 |